Stock ZLAB ZAI LAB LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Zai Lab Limited

Equities

ZLAB

US98887Q1040

Market Closed - Nasdaq
Other stock markets
 21:00:00 31/05/2024 BST 		5-day change 1st Jan Change
17.78 USD -2.25% Intraday chart for Zai Lab Limited -0.78% -34.94%
05-24 Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower MT
05-22 Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower
MT
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise
MT
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
BU
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
CI
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
AQ
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug
MT
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
MT
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
BU
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
CI
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading
MT
Zai Lab Announces Participation in May and June Investor Conferences
BU
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator
MT
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
BU
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy in China
CI
Zai Lab Announces Approval of AUGTYRO for Patients with ROS1-positive NSCLC by China's NMPA
AQ
Asian Equities Traded in the US as American Depositary Receipts Begin Week Higher
MT
Zai Lab Says China Approves New Drug Application for Lung Cancer Treatment Augtyro
MT
Zai Lab's Cancer Drug Gets NDA Approval in China
MT
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
BU
Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China?s NMPA
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZLAB Stock
  4. News Zai Lab Limited